| Trial ID: | L7392 |
| Source ID: | NCT02236754
|
| Associated Drug: |
18 F-Fp-Dtbz
|
| Title: |
Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02236754/results
|
| Conditions: |
Healthy Volunteers|Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: 18 F-FP-DTBZ|RADIATION: PET Scanning
|
| Outcome Measures: |
Primary: Mean VMAT2 Functional Binding Capacity in the β Cells to 18 F-FP-DTBZ, The VMAT2 functional binding capacity in the body and tail of the pancreas is calculated as BPND (VMAT2 binding potential) × PET ROI (region-of-interest) Volume. BPND is unitless, and ROI unit is mL. Higher values of the VMAT functional binding capacity indicates greater β cell mass., Up to 2 months from enrollment |
|
| Sponsor/Collaborators: |
Sponsor: Columbia University | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
23
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2013-07-02
|
| Completion Date: |
2014-04-23
|
| Results First Posted: |
2024-07-23
|
| Last Update Posted: |
2024-07-23
|
| Locations: |
Naomi Berrie Diabetes Center, New York, New York, 10032, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02236754
|
